The pharma giant struck a licensing deal to gain access to delivery technologies developed by U.S. startup Vivtex., to deepen its pipeline of next-generation obesity drugs.
About the Author
Discover more from InfoVera USA
Subscribe to get the latest posts sent to your email.
